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Objective: Disease-modifying osteoarthritis drugs (DMOADs) are under development. Our goal was to
determine efﬁcacy, toxicity, and cost thresholds under which DMOADs would be a cost-effective knee OA
treatment.
Design: We used the Osteoarthritis Policy Model, a validated computer simulation of knee OA, to compare
guideline-concordant care to strategies that insert DMOADs into the care sequence. The guideline-
concordant care sequence included conservative pain management, corticosteroid injections, total knee
replacement (TKR), and revision TKR. Base case DMOAD characteristics included: 50% chance of sus-
pending progression in the ﬁrst year (resumption rate of 10% thereafter) and 30% pain relief among those
with suspended progression; 0.5%/year risk of major toxicity; and costs of $1,000/year. In sensitivity an-
alyses, we varied suspended progression (20e100%), pain relief (10e100%), major toxicity (0.1e2%), and
cost ($1,000e$7,000). Outcomes included costs, quality-adjusted life expectancy, incremental cost-
effectiveness ratios (ICERs), and TKR utilization.
Results: Base case DMOADs added 4.00 quality-adjusted life years (QALYs) and $230,000 per 100 persons,
with an ICER of $57,500/QALY. DMOADs reduced need for TKR by 15%. Cost-effectiveness was most
sensitive to likelihoods of suspended progression and pain relief. DMOADs costing $3,000/year achieved
ICERs below $100,000/QALY if the likelihoods of suspended progression and pain relief were 20% and
70%. At a cost of $5,000, these ICERs were attained if the likelihoods of suspended progression and pain
relief were both 60%.
Conclusions: Cost, suspended progression, and pain relief are key drivers of value for DMOADs. Plausible
combinations of these factors could reduce need for TKR and satisfy commonly cited cost-effectiveness
criteria.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.: E. Losina, Orthopaedic and
Women’s Hospital, 75 Francis
-5338; Fax: 1-617-525-7900.
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Knee osteoarthritis (OA) is a prevalent and costly disease char-
acterized by structural changes in cartilage, bone, synovium, and
other joint structures1. Symptomatic knee OA is a leading cause of
disability, afﬂicting more than 9.3 million US adults2. The risk for
knee OA is growing substantially due to the aging population,
obesity epidemic, and an increasing rate of knee injuries in young,
active individuals1,3e7.
Current guidelines for knee OA care focus on pain relief and
functional improvement8e10. Pharmacologic therapies are onlyublished by Elsevier Ltd. All rights reserved.
E. Losina et al. / Osteoarthritis and Cartilage 21 (2013) 655e667656modestly efﬁcacious and have signiﬁcant associated toxicities. For
example, non-steroidal anti-inﬂammatory drugs (NSAIDs) pose
gastrointestinal and cardiovascular risks11e13. There are no cur-
rently approved OA treatments capable of slowing OA-related
structural progression or delaying the need for total knee replace-
ment (TKR). Several large pharmaceutical companies are in the late
stages of developing and testing disease-modifying OA drugs
(DMOADs), and promising agents that may both halt progression
and provide symptom relief are currently being studied14e17.
In light of ongoing efforts to develop DMOADs, we sought to
address several key questions: Can DMOADs be cost-effective, and
if so, at what levels of efﬁcacy, toxicity, and cost? How early in the
course of treatment should DMOADs be initiated? Do DMOADs
have the potential to reduce TKR utilization? To address these key
issues, we propose a novel framework in which model-based
evaluations of cost-effectiveness can be used to pre-evaluate new
treatment strategies before the treatments are actually in wide-
spread use. Estimating the effects of particular features of a medi-
cation on that medication’s cost-effectiveness can inform the
design of trials and provide performance targets.Methods
Analytic overview
We used the Osteoarthritis Policy (OAPol) Model, a validated
state-transition computer simulation model, to compare clinical
outcomes and costs between subjects receiving guideline-
concordant treatments (the standard of care (SoC)) and subjects
receiving SoC and DMOADs18,19. Outcomes included costs, quality-
adjusted life expectancy (QALE), incremental cost-effectiveness
ratios (ICERs, the ratio of change in costs to change in QALE), and
TKR utilization. In conformity with accepted practice, strategies
that increased cost while not increasing QALE relative to an alter-
native treatment strategy were referred to as “Dominated.” We
performed the analysis from the health systems perspective
(indirect costs were not included), with costs and QALE discounted
at a rate of 3%/year, as recommended by the Panel on Cost-
Effectiveness in Medicine20.The OAPol Model
The OAPol Model is a Monte Carlo simulationwith a 1-year cycle
length and health states deﬁned by knee OA severity, presence of
knee pain, comorbidities, and obesity18,19. Each year, subjects may
develop a comorbid condition, increase in body mass index (BMI),
progress in OA severity, and/or die. Progression of OA is deﬁned as
an increase by one KellgreneLawrence (KeL) radiographic grade
and is dependent on obesity status and sex21. The model considers
ﬁve comorbid conditions: coronary heart disease, diabetesmellitus,
chronic obstructive pulmonary disease, cancer, and muscu-
loskeletal disorders other than OA. The prevalences of these co-
morbid conditions depend on age, sex, race/ethnicity, and
obesity22e24. Each subject is followed until death, which may occur
in any health state. The OAPol Model uses underlying mortality
rates from US life tables with excess mortality due to speciﬁc co-
morbid conditions removed25. Individuals with comorbid condi-
tions have greater risk of death26,27. Subjects with knee OA may
receive OA treatments, which are characterized by the ability to
relieve pain and suspend OA progression, toxicity, and cost. OA
treatments may carry major (e.g., gastrointestinal bleeding) and
minor (e.g., dyspepsia, rash) toxicities, both of which decrease
quality of life and increase costs. Major toxicities lead to regimen
discontinuation and may also cause death.Each year, subjects accrue costs and changes in quality of life due
to OA or OA-related treatments and other underlying medical con-
ditions. Quality of life weights are assigned to capture preferences
for health states; a value of 1.0 denotes a state of perfect healthwhile
a value of zero denotes health states that are preferentially equiv-
alent to death28. Annual medical costs not directly attributable to
kneeOA are based on comorbidities and age22,23,30,33. These data are
presented in Table I. Running tallies of survival, quality-adjusted
survival, and costs are maintained for each individual and then
aggregated to compute average values for the cohort57. The fol-
lowing paragraphs describe the means of modeling the SoC and
DMOAD regimens.
Guideline-concordant OA care (SoC)
The SoC consists of four, sequentially more invasive regimens:
conservative pain management, including NSAIDs, acetaminophen,
supportive devices, and physical therapy (Regimen 1); cortico-
steroid injections (Regimen 2); primary TKR (Regimen 3); and
revision TKR (Regimen 4)8e10. Subjects progress to the next regi-
men in the sequence only when the current treatment fails or if
a major toxicity occurs. Failure of each regimen is assumed to be
detected in the year it occurs. Fundamental treatment character-
istics for the SoC are presented in Table I and described in detail in
the Technical Appendix.
DMOADs
We evaluated treatment strategies where DMOADs were used
after the ﬁrst SoC regimen and before the second SoC regimen.
Fig. 1 illustrates the treatment sequence for individuals receiving
DMOADs. There are two measures of DMOAD efﬁcacy: structural
efﬁcacy and pain relief. Structural efﬁcacy is deﬁned by a relative
reduction in the probability of progressing from one KeL grade to
the next. Subjects for whom DMOADs suspend OA progression (i.e.,
DMOADs exhibit structural efﬁcacy) remain at their current KeL
grade. Subjects in whom structural progression is suspended may
also experience pain relief and improvement in quality of life. To
ensure a conservative approach with respect to the clinical value of
DMOADs, we assumed that DMOAD-related pain relief is restricted
to subjects in whom knee OA progression is suspended. Delaying
progression at earlier stages of the disease prevents decrements in
quality of life associated with advanced OA (KeL grade 3 or 4).
Subjects experiencing toxicity (major or minor) have a decrement
in quality of life for that year and incur costs to treat the toxicity.
Major toxicity carries a small risk of death. Subjects are removed
fromDMOADs andmove on to the next treatment in the sequence if
DMOADs fail to suspend progression and that failure is detected, or
if a major toxicity occurs. Fig. 2 shows the OAPol Model process for
subjects receiving DMOADs.
Base case DMOAD characteristics and assumptions
As recommended by the Panel on Cost-effectiveness Analyses in
Health and Medicine, we chose a set of “base case” estimates of
DMOAD efﬁcacy, cost, and toxicity, to reﬂect the most likely set of
parameters of DMOADs based on a review of available literature
when possible and otherwise based on extensive discussions with
clinicians20. In the base case, we assumed that DMOADs suspended
OA progression in 50% of subjects. Among those in whom DMOADs
succeeded in suspending progression in the ﬁrst year, there was
a 10% failure rate of maintaining the suspension of progression in
every subsequent year. We further assumed that once disease
progression resumed, it could no longer be suspended via DMOADs.
For the base case analysis we chose to anchor pricing for DMOADs
at $1,000/year, similar to the cost of prescription NSAIDs30. In
addition to the baseline cost of DMOADs, we also considered the
Table I
Select OAPol Model inputs
Age at treatment initialization (mean  standard deviation) 53.54  14.39 Losina et al., 201231
Osteoarthritis progression (annual likelihood, %)
Obesity group KeL 2 to KeL 3 KeL 3 to KeL 4 Holt et al., 201119
Male Female Male Female
Non-obese 5.58 4.00 1.29 1.95
Obese 12.26 8.95 2.94 4.27
Quality of life utilities*
Utility for subjects with severe OA (KeL 3 or 4): 0.690 Losina et al., 200932
Number of comorbidities Age group Non-obese Obese
OA pain No OA pain OA pain No OA pain
0e1 25e44 0.814 0.955 0.781 0.921 NHANES, 2005e0822,23
45e64 0.806 0.952 0.773 0.918
65+ 0.884 0.943 0.850 0.909
2e3 25e44 0.721 0.903 0.688 0.870
45e64 0.713 0.901 0.679 0.867
65+ 0.791 0.891 0.757 0.858
>3 0.662 0.662 0.662 0.662
Annual direct medical costs (USD, 2010)
Number of comorbidities Age group OA pain No OA pain Pope et al., 200433
NHANES, 2005e822,23
CPI, 201034
MCBS, 200635
Red Book, 201030
0e1 25e34 $1,506 $1,302
35e44 $2,018 $1,814
45e49 $2,635 $2,431
50e54 $2,636 $2,432
55e59 $3,443 $3,239
60e64 $4,144 $3,940
65e69 $4,401 $4,198
70e74 $5,092 $4,888
75e79 $5,916 $5,712
80+ $7,709 $7,505
2e3 25e34 $6,856 $6,652
35e44 $7,368 $7,165
45e49 $7,958 $7,755
50e54 $7,959 $7,755
55e59 $8,436 $8,232
60e64 $9,136 $8,933
65e69 $9,060 $8,856
70e74 $9,750 $9,547
75e79 $10,575 $10,371
80+ $12,367 $12,163
>3 25e34 $12,710 $12,506
35e44 $13,223 $13,019
45e49 $11,954 $11,751
50e54 $11,955 $11,751
55e59 $13,105 $12,902
60e64 $13,806 $13,602
65e69 $15,570 $15,366
70e74 $16,260 $16,056
75e79 $17,084 $16,881
80+ $18,877 $18,673
(continued on next page)
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Table I (continued)
SoC treatments
Regimen 1: NSAIDs, acetaminophen,
physical therapy, assistive devices
First year Subsequent year failure
Pain relief (annual, %)y 64.00 24.00 Scott et al., 200036
First year Subsequent years
Major toxicity (annual, %) 0.38 0.38 Solomon et al., 200511, Goldstein et al., 199937
Minor toxicity (annual, %) 2.95 2.24 Bensen et al., 199952, Scott et al., 200036,
Silverstein et al., 199538
Cost (USD, 2010) $643 $483 Medicare, 201039e41, Red Book, 201030,
MCBS, 200635, Van Der Esch et al., 200342,
Grindrod et al., 201043
Regimen 2: Corticosteroid Injections First year Subsequent year failure
Pain relief (annual, %)y 64.00 19.00 Raynauld et al., 200344
First year Subsequent years
Major toxicity (annual, %) 0.00 0.00 Ayral, 200145
Minor toxicity (annual, %) 24.00 24.00 Ayral, 200145
Costy (USD, 2010) $437 $437 Medicare, 201039e41, MCBS, 200635
Regimen 3: Primary TKR First year Subsequent year failure
Pain relief (annual, %)z 86.20 4.00 Katz et al., 200746
First year Subsequent years
Major toxicity (annual, %) 1.33 0.00 Paxton et al., 201047, Katz et al., 200448
Minor toxicity (annual, %) 2.94 0.00 Katz et al., 200448
Costy (USD 2010) $19,065 $90 Medicare, 201039e41, HCUP, 200853,
Buntin et al., 200550, CPI, 201034,
Teeny et al., 200351
Regimen 4: Revision TKR First year Subsequent year failure
Pain relief (annual, %)z 74.30 5.60 Katz et al., 200746
First year Subsequent years
Major toxicity (annual, %) 0.96 0.00 Paxton et al., 201047, Katz et al., 200448
Minor toxicity (annual, %) 3.64 0.00 Katz et al., 200448
Costy (USD 2010) $24,631 $90 Medicare, 201039e41, HCUP, 200853,
Buntin et al., 200550, CPI, 201034,
Teeny et al., 200351
DMOADSx
ﬁrst year Subsequent years
Annual costs (base case) (USD, 2010)
Overall $1,000e$7,000 ($1,000)
Ofﬁce visits $132 $93 2010 Medicare Data39e41
Efﬁcacy (base case) %, annual 1st year Subsequent year failure
Halted progression (KeL 2e3)k 20e100 (50) 1e10 (10)
Pain relief{ (KeL 2e3)k 10e100 (30) 1e10 (1)
Toxicity (base case) %, annual 1st year Subsequent years
Major 0.5e2.0 (0.5) 0.5e2.0 (0.5)
Minor 9.50 7.27 Scott et al., 200036, Bensen et al., 199952
Toxicity outcomes
Major Cardiovascular Likelihood 32.3 Solomon et al., 200511
Mortality 6.02 HCUP, 200853
Utility# 0.778 Sullivan and Ghushchyan, 200654, NHANES,
2005e0822,23
Cost# $18,478 HCUP, 200853, CPI, 201034
Gastrointestinal Likelihood 67.7 Goldstein 200037
Mortality 2.93 HCUP 200853
Utility 0.859 Jansen 200755, NHANES 05-0822,23
Cost $9,408 HCUP 200853, CPI 201034
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E. Losina et al. / Osteoarthritis and Cartilage 21 (2013) 655e667 659cost of one ofﬁce visit per year: $132 in the ﬁrst year and $93 in
subsequent years (reﬂecting higher costs for new patient visits)58.
In practice, monitoring for drug failure is typically triggered
when patients report the persistence or recurrence of pain. Since
drug failures to suspend disease progression would be accom-
panied by pain, we therefore assumed that all DMOAD failures
would be detected in the year they occurred, resulting in dis-
continuation of DMOADs and allowing subjects to advance to the
next treatment regimen. We assumed in the base case that the
likelihood of pain relief was 30% given that progression was sus-
pended (that is, 15% overall likelihood of pain relief). Among
patients whose structural progression had been suspended due to
DMOADs and who experienced initial pain relief, there was
a 1%/year chance of losing pain relief. The failure to sustain pain
relief reﬂects a multitude of factors, including suboptimal adher-
ence and accumulation of additional risk factors such as injury.
We anchored values for both major and minor toxicities of
DMOADs to NSAID toxicity characteristics. The cohort of individuals
eligible to receive DMOADs will be similar to the population cur-
rently utilizing NSAIDs for OA pain; thus, acceptable DMOAD
adverse event rates are likely to be comparable to those of NSAIDs.
The likelihood of major toxicity was assumed to be 0.5% per year
based on the major toxicity risks of Cox-2 selective NSAIDs11,37.
DMOAD minor toxicity was modeled after the toxicity of non-
selective NSAIDs, with 9.50% risk in the ﬁrst year, and 7.27% risk
in all subsequent years36,52.
Cohort characteristics
We considered cohorts with a mean age of 53.5 years (standard
deviation 14.4 years) based on estimates of the average age of OA
diagnosis in the US31. Race/ethnicity, sex, and obesity distributions
for persons with diagnosed knee OA were derived from the Na-
tional Health Interview Survey (NHIS) 2007e200824. In the absence
of efﬁcacious DMOADs, annual OA progression rates (percentage of
subjects who worsened in KeL grade in a year) ranged from 1.29%
for non-obese, KeL grade 3 males to 12.26% for obese, KeL grade 2
males19. Annual underlying (not related to OA management)
medical costs (USD, 2010) ranged from $1,302 for young subjects
with at most one comorbid condition to $18,877 for older subjects
with greater than three comorbid conditions22,23,30,33e35. Quality of
life weights were derived by converting responses to general health
status questions in the National Health and Nutrition Examination
Survey (NHANES) 2005e2008 to health status ratings on a scale of
0e1.022,23,59,60. These ratings were then transformed to preference-
based utilities61. The values ranged from 0.95 for young, healthy
subjects with no OA pain to 0.66 for older subjects with several
comorbidities and knee pain. Advanced knee OA (deﬁned as
symptomatic KeL grades 3 or 4) had a quality of life weight of
0.6932. Prevalence of comorbid conditions were derived from
NHANES 2005e200822,23. Table I summarizes select cohort input
characteristics; additional details have been published else-
where18,19 or are presented in the Technical Appendix.
Sensitivity analyses
Two-way sensitivity analyses of DMOAD characteristics
We conducted 21 sets of two-way sensitivity analyses, varying
likelihood of suspending OA progression, pain relief, major toxicity,
loss of pain relief and/or resumption of OA progression, and costs.
We tested the sensitivity of DMOAD cost-effectiveness to variations
in the initial likelihood of suspended progression (20e100%),
failure to suspend progression in subsequent years (1e10%),
initial pain relief (10e100%), failure to relieve pain in subsequent
years (1e10%), cost ($1,000e$7,000), and major toxicity (0.1e2%)
PT,
NSAIDs*
Primary 
TKR
Revision 
TKR
DMOADs Injections
Death
Post-
TKR
Post-PT/
NSAIDs*
Post-
DMOADs
Post-
Injections
Post-
TKR
* This regimen includes physical therapy, NSAIDs, and acetaminophen 
Fig. 1. This ﬁgure shows the treatment sequence that each model subject will receive. Initially, subjects are on the ﬁrst regimen, which consists of NSAIDs, acetaminophen, and
physical therapy. Each year on the regimen, subjects are evaluated for regimen failure and for major toxicity. If the regimen fails or a major toxicity occurs, the subject will be
removed from the regimen and will move on either to the next regimen or to a post-treatment waiting period. Subjects will remain in the post-treatment waiting period until they
are determined to be eligible for the next treatment. Subjects in the DMOADs cohorts are eligible to receive DMOADs after the ﬁrst regimen (subjects not in the DMOADs cohort
move on to corticosteroid injections). Once DMOADs fail to relieve pain or a major toxicity occurs, subjects move on to receive corticosteroid injections either immediately, or after
a waiting period. This process continues through to TKR. Each year, subjects are evaluated for death; a subject may die at any point.
E. Losina et al. / Osteoarthritis and Cartilage 21 (2013) 655e667660in a series of two-way sensitivity analyses. By modeling DMOADs
with low levels of pain relief (10%), we incorporated the possibility
that DMOADs may not necessarily provide pain relief, even if they
suspend progression. These ranges were chosen to cover the
spectrum of possible DMOAD characteristics. Costs and toxicity
were anchored to known values for NSAIDs, based on recommen-
dations from experts in the ﬁeld.
Additional sensitivity analyses
In addition to varying levels of DMOAD efﬁcacy, toxicity, and
cost, we varied the timing of DMOAD administration, deﬁned by
where DMOADs are inserted in the current SoC sequence. We also
varied the placement of the regimens by switching the order of
Regimen 1 (NSAIDs, physical therapy, acetaminophen) and Regi-
men 2 (corticosteroid injections). We also tested the effect of
removing Regimen 2 (corticosteroid injections) from the treatment
sequence.
In a separate sensitivity analysis, we examined the value of
DMOADs while varying the baseline KeL grade distribution: (1)
initialized with 100% KeL grade 1 OA, and (2) initialized with 50%
KeL grade 1 and 50% KeL grade 2 OA.
Finally, we conducted a sensitivity analysis using data for dox-
ycycline, which has been suggested to have disease-modifying
properties. One published study showed that doxycycline could
reduce progression by up to 40% while doxycycline has not been
shown to have any effect on symptoms29. We modeled minor
gastrointestinal toxicities (the most signiﬁcant toxicity reported in
the study) occurring at a rate of 7% annually. Costs were estimated
at $200 annually according to the Red Book30.Results
Base case analysis (Table II, top row)
Clinical beneﬁts of DMOADs
The QALE among persons with knee OA who received the SoC
was estimated at 14.21 quality-adjusted life years (QALYs) dis-
counted (22.22 QALYs undiscounted). Adding base case DMOADs as
the second-line regimen in the treatment sequence (after NSAIDs
and physical therapy but before corticosteroid injections) led to an
estimated QALE of 14.25 QALYs.
Among knee OA patients receiving the current SoC, 11.00% un-
derwent TKR within 10 years of treatment initiation, with a 52.37%
lifetime risk of primary TKR. Adding base case DMOADs as the
second-line regimen reduced the 10-year risk of TKR by 46%, with5.99% of the DMOADs cohort receiving TKR within 10 years of
treatment initiation. Moreover, DMOADs reduced lifetime risk of
TKR by 15%, with 44.35% of the DMOADs cohort receiving primary
TKR.
Cost-effectiveness of DMOADs
Priced at $1,000 annually, the cost-effectiveness of DMOADs
offered as the second-line regimen for those diagnosed with knee
OA was estimated at $57,500/QALY gained.
Guidance for the prospective evaluation of DMOADs regimens
Fig. 3 shows the minimum degree of structural OA progression
suspension and pain relief at which DMOADs might be considered
cost-effective using three different cost-effectiveness thresholds:
$50,000/QALY, $100,000/QALY, and $150,000/QALY. Assuming
DMOADs are associated with 0.5% risk of major toxicity and failure
of DMOADs is diagnosed in the year it occurs, DMOADs costing
$1,000/person/year would achieve ICERs below $50,000/QALY if
they could suspend OA progression by at least 60% and provide
concurrent pain relief in at least 30% of those with suspended OA
progression. DMOADs that cost $3,000 or $5,000 would attain
ICERs below $100,000/QALY if they could suspend OA progression/
lead to pain relief by at least 20%/70% or 60%/60%. ICERs below
$150,000/QALY could be achieved by DMOADs costing $7,000/
person/year if they could suspend structural progression by at least
20% and lead to concomitant pain relief in at least 90% of thosewith
suspended OA progression. Fig. 3 shows that DMOADs costing
$1,000, suspending progression in 100% of cases, and leading to 20%
pain relief would provide similar value as more expensive DMOADs
($3,000/person/year) that suspend progression in 20% of cases, and
relieve pain in 70% of cases. The same value would also be achieved
by a more expensive DMOAD ($5,000) with pain relief and sus-
pended progression at 60%. DMOADs costing $7,000 were unlikely
to attain ICERs of $50,000/QALY, even if they were 100% effective in
both suspending structural progression and relieving pain.
Sensitivity analyses
Select, two-way sensitivity analyses are presented in Fig. 4 and
Tables II and III. Additional two-way sensitivity analyses are pre-
sented in the Technical Appendix. The timing of DMOAD admin-
istration (anywhere in the sequence prior to TKR) did not have
a meaningful impact on the cost-effectiveness of DMOAD therapy
(results not shown).
Yes
Update comorbidities and obesity. If 
DMOADs failed to suspend progression, 
assess whether K-L grade will increase. 
Move on to the next model cycle.
Accumulate DMOAD costs
Suspends
progression
Pain
relief
No
Yes
For subjects who have been determined to live and who 
have not yet recieved or are on DMOADs
No
Failure 
detected
Yes
No
QoL† increase
Cost decrease
Toxicity
No
Subject will be removed 
from DMOADs in the 
following cycle
MajorNo
Yes
Subject will be 
removed from 
DMOADs in the 
following cycle.
QoL decrease, Cost 
increase
Death
Yes
YesNo
End Subject 
Life Cycle
QoL decrease
Cost increase
†QoL – quality of life
QoL decrease
Cost increase
Fig. 2. This ﬁgure depicts the pathway of a hypothetical subject in the OAPol Model receiving DMOADs. When DMOADs are discontinued, subjects will be evaluated for the
treatment immediately following DMOADs.
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the degree of suspended progression and pain relief within clinically
plausible ranges (50e70% for suspended progression and 30e50% for
pain relief). When DMOADs were priced at $1,000/year with major
toxicity risks at 0.5%/year, DMOADs were likely to have cost-
effectiveness ratios below $100,000 compared to the SoC (no
DMOADs). The proportion of the cohort receiving TKR depended on
the likelihood that DMOADs suspended progression; base case
DMOADs as the second-line regimen (50% suspended progression,
30% concomitant pain relief) resulted in 44.35% lifetime risk for TKR.Increasing suspended progression to 70% decreased lifetime risk of
TKR to 41.31%. Fig. 4 (upper left box) portrays cost-effectiveness ratios
of DMOADs-based strategies for expanded ranges of suspended
progression and pain relief. Results of these two-way sensitivity an-
alyses suggest that pain relief 10% or lower led to a lower QALE in
patients receiving DMOADs compared to those who did not have
a DMOADs-based regimen as a part of their treatment strategy. Pain
relief levelsof20%or lower resulted ineither lowerQALE (in scenarios
where suspended OA progression was <60%) or ICERs greater than
$150,000 if suspended progression rates ranged from 60 to 70%.
Table II
Two-way sensitivity analysis of DMOAD pain relief and suspended progression
Suspended
progression
Pain relief Treatment strategy Avg. QALE Avg. cost ICER Proportion of cohort
receiving primary TKR
50% Base case 30% (15% overall)z SoC* 14.21 $115,800 52.37%
SoC þ DMOADsy 14.25 $118,100 $57,500 44.35%
40% (20% overall) SoC 14.21 $115,800 52.37%
SoC þ DMOADs 14.28 $118,000 $31,400 44.34%
50% (25% overall) SoC 14.21 $115,800 52.37%
SoC þ DMOADs 14.32 $118,000 $20,000 44.33%
60% 30% (18% overall) SoC 14.21 $115,800 52.37%
SoC þ DMOADs 14.26 $118,400 $52,000 42.82%
40% (24% overall) SoC 14.21 $115,800 52.37%
SoC þ DMOADs 14.30 $118,300 $27,800 42.82%
50% (30% overall) SoC 14.21 $115,800 52.37%
SoC þ DMOADs 14.35 $118,200 $17,100 42.83%
70% 30% (21% overall) SoC 14.21 $115,800 52.37%
SoC þ DMOADs 14.28 $118,600 $40,000 41.31%
40% (28% overall) SoC 14.21 $115,800 52.37%
SoC þ DMOADs 14.33 $118,600 $23,300 41.30%
50% (35% overall) SoC 14.21 $115,800 52.37%
SoC þ DMOADs 14.38 $118,500 $15,900 41.31%
* SoC sequence: conservative pain management (NSAIDs, acetaminophen, physical therapy), corticosteroid injections, primary TKR, revision TKR.
y SoC þ DMOADs sequence: conservative pain management, DMOADs, corticosteroid injections, primary TKR, revision TKR.
z Overall pain relief is calculated as (% pain relief given suspended progression) (% suspended progression); the top row of this table corresponds with 30% pain relief given
suspended progression, 50% suspended progression, and thus 15% overall pain relief.
Fig. 3. Threshold efﬁcacy, cost, and life expectancy associated with DMOADs treatment. This ﬁgure describes threshold efﬁcacy for alternative willingness-to-pay thresholds, shown
in blue ($50,000/QALY), green ($100,000/QALY), and yellow ($150,000/QALY). Squares represent efﬁcacy thresholds for DMOADs costing $1,000/person/year, triangles e $3,000/
person/year, circles e $5,000/person/year, and diamonds e $7,000/person/year. The vertical axis shows the per person discounted QALE and the horizontal axis shows the per
person discounted lifetime cost. The black square in the lower left corner represents the per person life expectancy and lifetime cost in a program with no DMOADs intervention.
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Fig. 4. Each box in this ﬁgure represents a single two-way analysis e for instance varying cost ($1,000e$3,000) and toxicity (0.1e2%) of DMOADs. The shade of each block in the
quadrant represents the level of cost-effectiveness for that particular DMOAD in comparison to the SoC. The darkest shades are the lowest levels of cost-effectiveness, and the
lightest shades represent the highest levels of cost-effectiveness. Blocks are shaded black if the particular DMOAD decreased QALE relative to the SoC, and thus were dominated. The
quadrants are organized such that the most beneﬁcial combination of DMOAD parameters appears in the bottom right-hand corner of each square (for example, lowest cost, $1,000,
and highest level of pain relief, 70%), and the least beneﬁcial combination of DMOAD parameters appears in the top left-hand corner of each square (for example, highest cost,
$3,000, and lowest pain relief, 10%).
Table III
Two-way sensitivity analysis of DMOAD cost and pain relief, suspended progression, or major toxicity
Treatment strategy Avg. QALE $1,000 $2,000 $3,000
Avg. cost ICER Avg. cost ICER Avg. cost ICER
Pain relief 30% (base case) SoC* 14.21 $115,800 $115,800 $115,800
SoC þ DMOADsy 14.25 $118,100 $57,500 $121,600 $145,000 $125,200 $235,000
40% SoC 14.21 $115,800 $115,800 $115,800
SoC þ DMOADs 14.28 $118,000 $31,400 $121,600 $82,900 $125,100 $132,900
50% SoC 14.21 $115,800 $115,800 $115,800
SoC þ DMOADs 14.32 $118,000 $20,000 $121,500 $51,800 $125,100 $84,500
Suspended progression 50% (base case) SoC 14.21 $115,800 $115,800 $115,800
SoC þ DMOADs 14.25 $118,100 $57,500 $121,600 $145,000 $125,200 $235,000
60% SoC 14.21 $115,800 $115,800 $115,800
SoC þ DMOADs 14.26 $118,400 $52,000 $122,500 $134,000 $126,600 $216,000
70% SoC 14.21 $115,800 $115,800 $115,800
SoC þ DMOADs 14.28 $118,600 $40,000 $123,300 $107,100 $128,000 $174,300
Major toxicity 1% SoC 14.21 $115,800 $115,800 $115,800
SoC þ DMOADs 14.24 $118,100 $76,700 $121,700 $196,700 $125,100 $310,000
0.5% (base case) SoC 14.21 $115,800 $115,800 $115,800
SoC þ DMOADs 14.25 $118,100 $57,500 $121,600 $145,000 $125,200 $235,000
0.1% SoC 14.21 $115,800 $115,800 $115,800
SoC þ DMOADs 14.26 $118,000 $44,000 $121,700 $118,000 $125,300 $190,000
* SoC sequence includes: conservative pain management (NSAIDs, acetaminophen, physical therapy), corticosteroid injections, primary TKR, revision TKR.
y SoC þ DMOADs sequence includes: conservative pain management, DMOADs, corticosteroid injections, primary TKR, revision TKR.
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E. Losina et al. / Osteoarthritis and Cartilage 21 (2013) 655e667664Fig. 4 also suggests that the cost-effectiveness of DMOADs was
very sensitive to the degree of initial pain relief, as well as loss of
pain relief beneﬁts in subsequent years, if initial pain relief was
between 30% and 50%. Major toxicity rates played an important
role, especially if levels of suspended progression were modest
(20e50%).
Table III presents results of two-way sensitivity analyses
examining the impact of DMOAD cost, efﬁcacy, and toxicity.
Improved pain relief (50%) achieved concurrently with suspended
progression of 50% led to very favorable cost-effectiveness ratios
(<$50,000/QALY); however, ICERs increased over $50,000/QALY
when DMOADs were priced at $2,000 or $3,000 annually. Priced at
$1,000/year, DMOADs had favorable ICERs across a wide range of
plausible values for pain relief, toxicity, and likelihood of suspended
progression.
ICERs for DMOADs did not vary substantially when we varied
the order of the regimens.When corticosteroid injections (Regimen
2) were received before Regimen 1 in the treatment sequence,
DMOADs still carried an ICER of $75,000/QALY. If corticosteroid
injections were removed from the treatment sequence altogether,
DMOADs carried an ICER of $31,000/QALY.
Altering KeL grade distribution at the time of knee OA diagnosis
did not lead to qualitative changes in ICERs. The DMOAD ICERs for
cohorts who were 100% KeL grade 1 at the time of diagnosis were
$38,000/QALY. The ICER for the 50% KeL grade 1 and 50% KL grade 2
cohort was $43,000/QALY.
Results of the sensitivity analyses modeling doxycycline as
a potential DMOAD showed that doxycycline was a dominated
strategy as it did not lead to meaningful improvements in quality
of life.
Discussion
Using the OAPol Model, a validated computer simulation of the
epidemiology and management of knee OA, we have demonstrated
that cost, efﬁcacy, and pain relief are the key drivers of value in
DMOADs. We have shown how these drivers trade off with one
another. In addition, we have described the many plausible com-
binations of these drivers which could reduce the need for TKR and
satisfy commonly cited cost-effectiveness criteria. There is no
general agreement about what deﬁnes “cost-effective.” In the
United States, maximum willingness-to-pay thresholds ranging
from $50,000/QALY to $150,000/QALY and beyond are widely
cited62e64.
The cost-effectiveness of DMOADs was highly sensitive to vari-
ations in those parameters with direct effects on quality of life,
particularly pain relief. Variations in the level of pain relief revealed
a distinct threshold of 20%, below which DMOADs would not offer
clinical beneﬁts relative to standard care. DMOADswith no intrinsic
pain-relieving capacity could only improve quality of life if slowing
down progression ultimately reduced pain. Our results validate the
importance of targeting pathways which will both reduce pro-
gression and offer pain relief.
Since improvements in quality of life are anchored in pain relief,
the cost-effectiveness of DMOADs ultimately depends on the level
of overall symptom relief achieved by suspended structural pro-
gression. Greater rates of suspended OA progression were asso-
ciated with a lower proportion of the cohort receiving TKR;
however, the reduced TKR rates did not translate to greater cost-
effectiveness unless DMOADs also offered pain relief because
while TKR is costly, it consistently provides pain relief. Thus, in
order to justify prolonged DMOAD use before TKR, even in cases of
suspended progression, DMOADs must offer pain relief.
Several important limitations of our analyses should be noted.
We used the KeL grade as a measure of OA progression65,66. Whilea magnetic resonance imaging -based (MRI) deﬁnition of OA and its
progression is receiving growing attention, the validation of MRI-
based markers is ongoing67. In order to address this limitation
and maintain conservative estimates of pain relief, we did not
model pain relief as automatically occurring in cases of suspended
progression; rather, in the base case, only 30% of subjects experi-
encing suspended progression also experienced pain relief. More-
over, in the model, the efﬁcacy of DMOADs was expressed in terms
of slowing or ‘suspending’ progression based on KeL grade. How-
ever, KeL grade is a relatively unresponsive marker of radiographic
change and its use may lead to increased time until DMOAD failure
detection68. Since conventional radiographs are a current SoC, our
analysis is consistent with clinical practice.
We assumed that failure of DMOADs is detected in the year it
occurs. While this assumption biases the results in favor of
DMOADs, it seems reasonable since monitoring for failure is trig-
gered by continuous or newly occurring pain.
We chose not to model indirect costs because, at present, there
are no data available on the impact of DMOADs on disability or
absenteeism. As more data become available, this will be a rich area
for future research.
NHIS instruments did not allow for separation between OA
occurring at the knee and OA occurring at other sites. The NHIS also
did not distinguish OA from gout, RA, lupus, or ﬁbromyalgia. These
ambiguities may distort the distributions of sex, BMI and race
assigned to persons with knee OA.
This analysis did not consider high-tibial osteotomy (a treat-
ment option for subjects with uni-compartmental disease) as part
of the standard treatment sequence because these procedures are
performed infrequently in the US49. To ensure that results are
generalizable to the overall population with knee OA, we chose to
simulate the most common OA treatments.
The cost-effectiveness thresholds will vary from country to
country. The results presented in this paper are based on cost and
quality of life data measured in the US. This paper offers method-
ology that could be used to assess cost-effectiveness of DMOADs in
other countries, using country-speciﬁc data on OA natural history,
progression, treatment costs, and potentially alternative thresholds
for economic value.
Although we only modeled the use of one DMOAD as part of the
OA treatment sequence, it is likely that multiple DMOADs will ul-
timately become available to patients. It is also possible that
DMOADs are more likely to offer pain relief for subjects at earlier
stages of OA. However, we did not model varying levels of pain
relief based on current KeL grade. In this case, it would be critical to
offer DMOADs early in the treatment sequence, thus catching pa-
tients before they progress to more severe OA.
The results of our analyses showed that in the absence of
DMOADs, the lifetime risk of TKR among those with symptomatic
knee OA was approximately 50%. These results suggest higher TKR
rates than estimated in data derived from large cohort studies such
as the Osteoarthritis Initiative (OAI)69. There are several reasons for
the difference between our model-based estimates and OAI data:
(1) persons intending to undergo TKR within 18 months were
excluded from OAI, and (2) OAI-based estimates, which indicate
a 1%/year conversion to TKR, include data from both incident and
prevalent cohorts, with a substantial number of persons at KeL
grade 1. In contrast, our model-based estimates used incidence of
TKR data derived from the Multicenter Osteoarthritis Study
(MOST), which assumes that only subjects with KeL grade 3 or
greater were eligible for TKR. Among subjects in the OAI with KeL
grade 3 or 4 OA, the conversion to TKR was estimated at about 10%/
year69,70. Furthermore, this rate of conversion to TKR among those
at KeL grade 3 or 4was consistent with nationwide estimates of the
number of TKRs performed in the US71.
E. Losina et al. / Osteoarthritis and Cartilage 21 (2013) 655e667 665To the best of our knowledge, the results of the analyses docu-
mented here comprise the ﬁrst pre-evaluation of the effectiveness,
costs, and cost-effectiveness of DMOAD therapy for knee OA. We
have examined the sensitivity of DMOAD value to variations in
a wide spectrum of characteristics, most notably efﬁcacy, toxicity,
and costs. Our ﬁndings may provide critical insights for clinical trial
planning and ensure that drug manufacturers focus the develop-
ment of new regimens on parameters that will affect quality of life,
in particular, pain relief. These analyses also offer a new approach in
which simulation modeling can be efﬁciently used to evaluate new
treatment strategies under development before the implementa-
tion of costly clinical trials.
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